xmlui.ArtifactBrowser.ItemViewer.show_simple

dc.contributor.authorLinhares, Alexandre da Costa-
dc.contributor.authorGabbay, Yvone Benchimol-
dc.contributor.authorMascarenhas, Joana D'Arc Pereira-
dc.contributor.authorFreitas, Ronaldo Barros de-
dc.contributor.authorOliveira, Consuelo Silva de-
dc.contributor.authorBellesi, Newton-
dc.contributor.authorMonteiro, Talita Antônia Furtado-
dc.contributor.authorLins-Lainson, Zéa Constante-
dc.contributor.authorRamos, Francisco Lúzio de Paula-
dc.contributor.authorValente, Sebastião Aldo da Silva-
dc.date.accessioned2018-07-13T13:02:45Z-
dc.date.available2018-07-13T13:02:45Z-
dc.date.issued1998-
dc.identifier.citationLINHARES, Alexandre da Costa et al. Immunogenicidad, inocuidad y eficacia de una vacuna tetravalente obtenida por recombinación genética de rotavirus aislados de monos rhesus y seres humanos en Belém, Brasil Pan American Journal of Public Health, v. 3, n. 5, p. 326-336, 1998.pt_BR
dc.identifier.issn1020-4989-
dc.identifier.urihttp://patua.iec.gov.br//handle/iec/3224-
dc.description.abstractA tetravalent rhesus-human reassortant rotavirus (RRV-TV) vaccine (4 x 10(4) plaque-forming units/dose) was evaluated for safety, immunogenicity and efficacy in a prospective, randomized, double-blind, placebo-controlled trial involving 540 Brazilian infants. Doses of vaccine or placebo were given at ages, 1, 3 and 5 months. No significant differences were noted in the occurrence of diarrhoea or vomiting in vaccine and placebo recipients following each dose. Low-grade fever occurred on days 35 in 23% of vaccinees after the first dose, but not after the second or third doses of vaccine. An IgA antibody response to rhesus rotavirus (RRV) occurred in 58% of vaccinees and 33% of placebo recipients. Neutralizing antibody responses to individual serotypes did not exceed 20% when measured by fluorescent focus reduction, but exceeded 40% when assayed by plaque reduction neutralization. There were 91 cases of rotavirus diarrhoea among the 3-dose (vaccine or placebo) recipients during two years of follow-up, 36 of them among children given the vaccine. Overall vaccine efficacy was 8% (P = 0.005) against any diarrhoea and 35% (P = 0.03) against any rotavirus diarrhoea. Protection during the first year of follow-up, when G serotype 1 rotavirus predominated, was 57% (P = 0.008), but fell to 12% in the second year. Similar results were obtained when analysis was restricted to episodes in which rotavirus was the only identified pathogen. There was a tendency for enhanced protection by vaccine against illness associated with an average of 6 or more stools per day. These results are sufficiently encouraging to warrant further studies of this vaccine in developing countries using a higher dosage in an attempt to improve its immunogenicity and efficacy.pt_BR
dc.language.isoesppt_BR
dc.publisherWorld Health Organizationpt_BR
dc.rightsAcesso Abertopt_BR
dc.titleImmunogenicidad, inocuidad y eficacia de una vacuna tetravalente obtenida por recombinación genética de rotavirus aislados de monos rhesus y seres humanos en Belém, Brasilpt_BR
dc.typeArtigopt_BR
dc.subject.decsPrimaryRotavirus / patogenicidadept_BR
dc.subject.decsPrimaryRotavirus / imunologiapt_BR
dc.subject.decsPrimaryVacinas contra Rotavirus / administração & dosagempt_BR
dc.subject.decsPrimaryVacinas contra Rotavirus / imunologiapt_BR
dc.subject.decsPrimaryVacinas / imunologiapt_BR
dc.subject.decsPrimaryVacina contra Difteria, Tétano e Coqueluche / imunologiapt_BR
dc.creator.affilliationMinistério da Saúde. Fundação Nacional de Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Fundação Nacional de Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Fundação Nacional de Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Fundação Nacional de Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Fundação Nacional de Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationClínica de Medicina Preventiva de Pará. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Fundação Nacional de Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Fundação Nacional de Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Fundação Nacional de Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Fundação Nacional de Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR


xmlui.dri2xhtml.METS-1.0.item-files-head

Thumbnail

xmlui.ArtifactBrowser.ItemViewer.head_parent_collections

xmlui.ArtifactBrowser.ItemViewer.show_simple